Lymphoma Clinical Trials

Showing 1181-1200 of 2,926 trials

Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma

NCT00574509

The purpose of this study is to assess the safety of 131I-anti-B1 Radioimmunotherapy when combined with high-dose BEAM or BEAC chemotherapy and hematopoietic stem cell transplantation. The study will also compare the difference in response rates and time to treatment failure between historical control patients receiving high-dose BEAM or BEAC chemotherapy with autologous hematopoietic stem cell transplant and patients receiving radioimmunotherapy and high-dose BEAM or BEAC chemotherapy with autologous hematopoietic stem cell transplant. Patients will receive escalating doses of radioimmunotherapy with anti-B1 radiolabeled with 131Iodine, high-dose carmustine, etoposide, cytarabine and Melphalan (BEAM) chemotherapy, and autologous hematopoietic stem cell transplant.

Lymphoma

University of Nebraska34 participantsStarted Mar 1996

Omaha, Nebraska, United States

TERMINATEDPhase 1/2

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02957019

Phase I/II, open-label, multicenter, prospective study.

Diffuse Large B-cell Lymphoma (DLBCL)

Philogen S.p.A.6 participantsStarted Jul 2013

Münster, Germany

COMPLETEDPhase 1

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

NCT04338659

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.

Advanced Malignant Tumors Lymphomas

Innovent Biologics (Suzhou) Co. Ltd.22 participantsStarted Jan 2021

Los Angeles, California, United States • Westwood, Kansas, United States • Jackson, Mississippi, United States +1 more locations

Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

Related Searches

Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)

Navigating the Clinical Research Process for Lymphoma

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

L19IL2/L19TNF in Skin Cancer Patients

National Registry of Rare Kidney Diseases

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery

Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma

Transplantation After Complete Response In Patients With T-cell Lymphoma

Durvalumab in Pediatric and Adolescent Patients

Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors